Gentherm Inc is a global leader in developing advanced thermal management technologies, focusing primarily on enhancing comfort and safety in vehicles
The company designs and manufactures innovative solutions for temperature regulation, including heated and cooled seating systems, climate control seats, and battery thermal management systems for electric vehicles. Gentherm's cutting-edge products aim to improve the overall driving experience, ensuring that users enjoy optimal comfort regardless of external weather conditions. Committed to sustainability and innovation, Gentherm also explores opportunities to expand its applications beyond the automotive sector, providing thermal management solutions for other industries, such as medical and industrial markets.
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 150 points on Wednesday. The Dow traded down 0.39% to 38,412.53 while the NASDAQ fell 1.06% to 15,464.67. The S&P 500 also fell, dropping, 0.47% to 4,952.19.
Companies Reporting Before The Bell • Gatos Silver (NYSEGATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.
Shares of International Flavors & Fragrances Inc. (NYSEIFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly dividend approximately 50% to 40 cents per share.
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 0.5% on Wednesday. The Dow traded down 0.16% to 38,503.94 while the NASDAQ fell 0.47% to 15,557.94. The S&P 500 also fell, dropping, 0.11% to 4,969.94.
Gentherm (NASDAQTHRM) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings Gentherm beat estimated earnings by 32.08%, reporting an EPS of $0.7 versus an estimate of $0.53.
Gainers Windtree Therapeutics Inc (NASDAQWINT) shares jumped 75.3% to $0.2921. Windtree Therapeutics has been granted U.S. patent number 11,583,540 titled "Istaroxime-Containing Intravenous Formulation For The Treatment Of Acute Heart Failure."
